Johnson & Johnson (J&J) has recorded a notable 38.4% stock increase over the past six months, even as it faces over 73,000 lawsuits linked to its talc products. The company projects growth in its Innovative Medicine sector of 5% to 7% from 2025 to 2030, underpinned by its substantial $32 billion investment in R&D and acquisitions this year. While J&J anticipates sales growth across all divisions in 2026, recent court rulings have ordered significant damages for talc-related cases, showcasing the ongoing risk posed by legal challenges.
“Johnson & Johnson’s JNJ stock · has risen · 38.4% in the past six months · 38.4%”
“J&J’s 50-day SMA · has been above · the 200-day SMA · since mid-June 2025”
“J&J expects · the Innovative Medicine business to grow · 5% to 7% from 2025 to 2030 · 5% to 7%”
“J&J invested · over · $32 billion in R&D and M&A in 2025 · over $32 billion”
“J&J gained approval · for new products · in 2025 · true”
“J&J lost U.S. patent exclusivity · of Stelara · in 2025 · in 2025”
“J&J faces · more than 73,000 lawsuits · for its talc-based products · more than 73,000”
“J&J expects · sales growth in both segments · to be higher in 2026 · higher in 2026”
“J&J's diversification helps · it to withstand · economic cycles more effectively · true”
“Johnson & Johnson · Change · Stock Change · +4.96”
“Johnson & Johnson · last price · last · 248.43”
“Johnson & Johnson · Last · price · 248.43”
